SCHEMBL3980033

SCHEMBL3980033

Nc1ccc2c(c1C(=O)O)CCCC2

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
METAP2 P50579 12/20 0.57
ALDH1A1 P00352 3/20 0.39
NOS3 P29474 1/20 0.39
NOS1 P29475 1/20 0.39
NOS2 P35228 1/20 0.39
CDC25B P30305 1/20 0.38
CASP6 P55212 1/20 0.38
RCE1 Q9Y256 1/20 0.38
LMNA P02545 1/20 0.37
GAA P10253 1/20 0.37
MAPT P10636 1/20 0.37
HPGD P15428 1/20 0.37
BCL2L1 Q07817 1/20 0.37
BAD Q92934 1/20 0.37
KDM4E B2RXH2 1/20 0.37
GFER P55789 1/20 0.37
KMT2A Q03164 1/20 0.37
RXFP1 Q9HBX9 1/20 0.37
IP6K1 Q92551 1/20 0.37
RXRA P19793 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13091616 0.96 METAP2 (0.53) METAP2ALDH1A1NOS3NOS1NOS2
SCHEMBL819226 0.81 METAP2 (0.51) METAP2ALDH1A1HPGDBCL2L1BAD
SCHEMBL3980109 0.80 METAP2 (0.43) METAP2ALDH1A1GAAMAPTHPGD
SCHEMBL11724129 0.79 METAP2 (0.50) METAP2ALDH1A1BCL2L1BADRXRA
SCHEMBL29288510 0.78 METAP2 (0.49) METAP2ALDH1A1BCL2L1BADRXRA
SCHEMBL22102553 0.78 METAP2 (0.49) METAP2ALDH1A1CASP6LMNAMAPT
SCHEMBL819555 0.77 METAP2 (0.48) METAP2ALDH1A1CASP6HPGDKDM4E
SCHEMBL22102573 0.76 METAP2 (0.48) METAP2ALDH1A1LMNAKMT2A
SCHEMBL25082656 0.76 METAP2 (0.38) METAP2ALDH1A1NOS3NOS1NOS2
SCHEMBL1506559 0.76 ALDH1A1 (0.43) METAP2ALDH1A1GAAMAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230165892-A1 POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF SYNDEVRX, INC. (US) 2023-06-01 US disclosed
US-9895449-B2 Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof SYNDEVRX, INC. (US) 2018-02-20 US disclosed
US-7491718-B2 Sulfonamides having antiangiogenic and anticancer activity ABBOTT LABORATORIES (US) 2009-02-17 US disclosed
EP-1549613-A1 SULFONAMIDES HAVING ANTIANGIOGENIC AND ANTICANCER ACTIVITY Abbott Laboratories (US) 2005-07-06 EP disclosed
US-20040167128-A1 Sulfonamides having antiangiogenic and anticancer activity ABBVIE INC. 2004-08-26 US disclosed
US-20040157836-A1 Sulfonamides having antiangiogenic and anticancer activity ABBOTT LABORATORIES 2004-08-12 US disclosed
WO-2004033419-A1 SULFONAMIDES HAVING ANTIANGIOGENIC AND ANTICANCER ACTIVITY ABBOTT LABORATORIES (US) 2004-04-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040167128-A1 Sulfonamides having antiangiogenic and anticancer activity METAP2, METAP1, DNPEP METAP2 1/4885ALDH1A1 3463/4885NOS3 1094/4885
US-20230165892-A1 POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF METAP2, MTX2, METAP1 METAP2 1/4885ALDH1A1 4179/4885NOS3 4305/4885
US-20040157836-A1 Sulfonamides having antiangiogenic and anticancer activity METAP2, METAP1, DNPEP METAP2 1/4885ALDH1A1 3463/4885NOS3 1094/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.